SCHEMBL4946334

SCHEMBL4946334

CC(C)CN(N)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 7/20 0.50
POLB P06746 1/20 0.37
APOBEC3A P31941 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
TAAR1 Q96RJ0 4/20 0.37
SLC6A2 P23975 2/20 0.37
MAOA P21397 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
HTR2A P28223 1/20 0.37
HRH1 P35367 1/20 0.37
CYP2A6 P11509 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491244 0.83 AOC3 (0.47) AOC3POLBAPOBEC3AAPOBEC3GTAAR1
SCHEMBL28740896 0.82 AOC3 (0.41) AOC3TAAR1SLC6A2SLC6A4ALDH1A1
SCHEMBL6490879 0.81 AOC3 (0.41) AOC3POLBAPOBEC3AAPOBEC3GTAAR1
SCHEMBL6487531 0.81 AOC3 (0.66) AOC3TAAR1MAOAHTR2AHRH1
SCHEMBL21731485 0.79 AOC3 (0.44) AOC3SIGMAR1HTR2AHRH1ALDH1A1
SCHEMBL3824994 0.78 AOC3 (0.43) AOC3TAAR1SLC6A2MAOASLC6A4
SCHEMBL6477129 0.78 AOC3 (0.38) AOC3HTR2AHRH1ALDH1A1LMNA
SCHEMBL6487412 0.78 AOC3 (0.40) AOC3POLBAPOBEC3AAPOBEC3GALDH1A1
SCHEMBL2399169 0.76 TSHR (0.45) AOC3POLBAPOBEC3AAPOBEC3GSLC6A2
SCHEMBL92732 0.76 POLB (0.52) AOC3POLBAPOBEC3AAPOBEC3GSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456201-B2 Pharmaceutically active compounds and methods of use LABORATOIRES SERONO SA (CH) 2008-11-25 US disclosed
EP-1441724-B8 METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS SERONO LAB (CH) 2007-10-17 EP disclosed
EP-1441724-B1 METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS APPLIED RESEARCH SYSTEMS (AN) 2007-09-05 EP disclosed
EP-1282418-B1 USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY APPLIED RESEARCH SYSTEMS (AN) 2005-08-17 EP disclosed
US-6914069-B2 Pharmaceutically active compounds and methods of use APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-07-05 US disclosed
WO-2005040127-A1 NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME LG LIFE SCIENCES LTD. (KR) 2005-05-06 WO disclosed
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 US disclosed
US-20050026985-A1 Pharmaceutically active compounds and methods of use APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. 2005-02-03 US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
US-20040198799-A1 Methods of increasing endogenous testosterone levels LABORATOIRES SERONO SA (CH) 2004-10-07 US disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 US disclosed
EP-1441724-A1 METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS Applied Research Systems ARS Holding S.A. (AN) 2004-08-04 EP disclosed
WO-2003026649-A1 METHODS OF INCREASING ENDOGENOUS TESTOSTERONE LEVELS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-04-03 WO disclosed
EP-1282418-A2 USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY Serono Reproductive Biology Institute, Inc. (US) 2003-02-12 EP disclosed
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP disclosed
US-20020132844-A1 Pharmaceutically active compounds and methods of use MERCK SERONO SA (CH) 2002-09-19 US disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed
WO-2001087287-A2 USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-11-22 WO disclosed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198799-A1 Methods of increasing endogenous testosterone levels SHBG, CYP17A1, NR5A1 AOC3 885/4885POLB 1754/4885APOBEC3A 3287/4885
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP AOC3 1365/4885POLB 1563/4885APOBEC3A 4171/4885
US-20020132844-A1 Pharmaceutically active compounds and methods of use CATSPER1, NASP, ACR AOC3 1718/4885POLB 1566/4885APOBEC3A 717/4885
US-20050026985-A1 Pharmaceutically active compounds and methods of use CATSPER1, NASP, ACR AOC3 1718/4885POLB 1566/4885APOBEC3A 717/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP AOC3 1365/4885POLB 1563/4885APOBEC3A 4171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.